HUP0102240A3 - Use of indigoid bisindole derivatives for the manufacture of a medicament to inhibit cyclin dependent kinases - Google Patents

Use of indigoid bisindole derivatives for the manufacture of a medicament to inhibit cyclin dependent kinases

Info

Publication number
HUP0102240A3
HUP0102240A3 HU0102240A HUP0102240A HUP0102240A3 HU P0102240 A3 HUP0102240 A3 HU P0102240A3 HU 0102240 A HU0102240 A HU 0102240A HU P0102240 A HUP0102240 A HU P0102240A HU P0102240 A3 HUP0102240 A3 HU P0102240A3
Authority
HU
Hungary
Prior art keywords
medicament
manufacture
cyclin dependent
dependent kinases
inhibit cyclin
Prior art date
Application number
HU0102240A
Other languages
English (en)
Original Assignee
Eisenbrand Gerhard
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from EP98109845A external-priority patent/EP0966963A1/en
Application filed by Eisenbrand Gerhard filed Critical Eisenbrand Gerhard
Publication of HUP0102240A2 publication Critical patent/HUP0102240A2/hu
Publication of HUP0102240A3 publication Critical patent/HUP0102240A3/hu

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404Indoles, e.g. pindolol
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D209/00Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04Indoles; Hydrogenated indoles
    • C07D209/30Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C07D209/40Nitrogen atoms, not forming part of a nitro radical, e.g. isatin semicarbazone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/06Antipsoriatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D209/00Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04Indoles; Hydrogenated indoles
    • C07D209/30Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C07D209/32Oxygen atoms
    • C07D209/34Oxygen atoms in position 2
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
HU0102240A 1998-05-29 1999-05-26 Use of indigoid bisindole derivatives for the manufacture of a medicament to inhibit cyclin dependent kinases HUP0102240A3 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP98109845A EP0966963A1 (en) 1998-05-29 1998-05-29 Use of indigoid bisindole derivatives as CDK1 inhibitors
EP99105693 1999-03-19
PCT/EP1999/003625 WO1999062503A2 (en) 1998-05-29 1999-05-26 Use of indigoid bisindole derivatives for the manufacture of a medicament to inhibit cyclin dependent kinases

Publications (2)

Publication Number Publication Date
HUP0102240A2 HUP0102240A2 (hu) 2001-11-28
HUP0102240A3 true HUP0102240A3 (en) 2003-05-28

Family

ID=26149292

Family Applications (1)

Application Number Title Priority Date Filing Date
HU0102240A HUP0102240A3 (en) 1998-05-29 1999-05-26 Use of indigoid bisindole derivatives for the manufacture of a medicament to inhibit cyclin dependent kinases

Country Status (14)

Country Link
EP (1) EP1079826B1 (hu)
JP (1) JP2002516851A (hu)
KR (1) KR20010078722A (hu)
AT (1) ATE233560T1 (hu)
AU (1) AU762830B2 (hu)
BR (1) BR9910810A (hu)
CA (1) CA2333661A1 (hu)
DE (1) DE69905712T2 (hu)
DK (1) DK1079826T3 (hu)
ES (1) ES2194468T3 (hu)
HU (1) HUP0102240A3 (hu)
IL (1) IL139914A0 (hu)
NO (1) NO20006027L (hu)
WO (1) WO1999062503A2 (hu)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6624171B1 (en) 1999-03-04 2003-09-23 Smithkline Beecham Corporation Substituted aza-oxindole derivatives
GB9904933D0 (en) 1999-03-04 1999-04-28 Glaxo Group Ltd Compounds
US6664285B1 (en) 1999-04-12 2003-12-16 Gerhard Eisenbrand Use of cell membrane penetrating indigoid bisindole derivatives
HUP0200724A3 (en) * 1999-04-12 2002-10-28 Eisenbrand Gerhard Indigoid bisindole derivatives and pharmaceurical compositions containing them
WO2002030410A2 (en) * 2000-10-10 2002-04-18 Board Of Regents, The University Of Texas System Suppression of cyclin kinase activity for prevention and treatment of infections
DE10053474A1 (de) * 2000-10-24 2002-05-02 Schering Ag Schwefelhaltige Indirubinderivate, deren Herstellung und Verwendung
DE10061162A1 (de) * 2000-11-30 2002-07-11 Schering Ag Aryl-substituierte Indirubinderivate, deren Herstellung und Verwendung
WO2002059123A2 (en) * 2000-12-18 2002-08-01 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Benzoylalkylindolepyridinium compounds and pharmaceutical compositions comprising such compounds
FR2821358B1 (fr) * 2001-02-27 2006-04-07 Aventis Pharma Sa Oxindoles inhibiteurs de cdk-1 et leur application en therapeutique
DE10114138C2 (de) * 2001-03-16 2003-03-27 Schering Ag Cdk-inhibitorische Indirubinderivate mit erhöhter Löslichkeit
DE10125763A1 (de) * 2001-05-17 2002-11-28 Schering Ag Verwendung selektiver Indirubinderivate als VEGF-R Inhibitoren
DE10129028A1 (de) * 2001-06-11 2003-01-02 Schering Ag Lösliche Cdk-inhibitorische Indirubinderivate
TW201041580A (en) * 2001-09-27 2010-12-01 Alcon Inc Inhibitors of glycogen synthase kinase-3 (GSK-3) for treating glaucoma
DE60237993D1 (de) * 2001-12-13 2010-11-25 Natrogen Therapeutics Inc Derivate von isoindigo, indigo und indirubin und deren verwendung bei der behandlung von krebs
US20050154046A1 (en) * 2004-01-12 2005-07-14 Longgui Wang Methods of treating an inflammatory-related disease
US6566341B1 (en) * 2001-12-13 2003-05-20 Natrogen Therapeutics, Inc. Derivative of isoindigo, indigo and indirubin for the treatment of cancer
US8563525B2 (en) 2004-01-12 2013-10-22 Natrogen Therapeutics International, Inc. Methods of treating an inflammatory-related disease
US7582670B2 (en) 2001-12-13 2009-09-01 Natrogen Therapeutics, Inc. Methods of treating an inflammatory-related disease
MXPA04009434A (es) * 2002-04-03 2005-01-25 Allergan Inc (3z)-3- (3 -hidroisobenzofuran- 1-iliden) -1, 3-dihidro- 2h-indol -2-onas como inhibidores de cinasa.
CN1199946C (zh) * 2002-10-29 2005-05-04 无锡杰西医药科技有限公司 一种特异性吲哚类化合物及制备方法与其在治疗和预防癌症等疾病中的应用
KR100588803B1 (ko) * 2004-01-27 2006-06-12 학교법인조선대학교 암세포주에 항암활성을 지닌 인디루빈 유도체
UA85594C2 (ru) * 2004-05-12 2009-02-10 Байер Кропсайенс Аг Применение производного индолинона для регулирования роста растений и способ регулирования роста сельскохозяйственных растений
MX2007001155A (es) * 2004-07-29 2007-08-14 Creabilis Therapeutics Spa Uso de inhibidores de k-252a y de quinasa para la prevencion o el tratamiento de patologias asociadas con hmgb1.
CN1329376C (zh) * 2005-09-19 2007-08-01 无锡杰西医药科技有限公司 一种n(1)-烃基-3′-肟基靛玉红衍生物(i)的制备方法及其医学应用
JP4587961B2 (ja) * 2006-01-16 2010-11-24 独立行政法人科学技術振興機構 神経因性疼痛治療剤
WO2010072399A1 (en) 2008-12-22 2010-07-01 Gerhard Eisenbrand 7-azaindirubins, 7'azaindirubins, 7,7'-diazaindirubins and the corresponding 3'-oxime ether derivatives thereof, their production and use as a medicament
EP2199292A1 (en) 2008-12-22 2010-06-23 Technische Universität Kaiserlautern 7-azaindirubins, 7'-azaindirubins, 7-7'-diazaindirubin and the corresponding 3'-oxime ether derivates: production thereof, their production and use as a medicament
FR2945747A1 (fr) 2009-05-25 2010-11-26 Centre Nat Rech Scient Composition pharmaceutique antitumorale comprenant un inhibiteur de cdks et un inhibiteur de la croissance cellulaire
FR2952818B1 (fr) * 2009-11-23 2013-05-31 Oreal Composition contenant au moins un precurseur de coloration derive d'indole, au moins un colorant indoline dione et au moins un compose organique liquide
KR101180030B1 (ko) 2010-02-05 2012-09-05 광주과학기술원 사이클린-의존적 키나제 저해제로서 항암 활성을 지닌 인디루빈-3'-옥심 유도체
US8524121B2 (en) * 2012-01-27 2013-09-03 Xerox Corporation Bi-indoline-dithione polymers
US20150087687A1 (en) 2012-03-23 2015-03-26 Dennis Brown Compositions and methods to improve the therapeutic benefit of indirubin and analogs thereof, including meisoindigo
CN103333161B (zh) * 2013-05-28 2015-09-30 滁州市洛达生物科技有限公司 1’-氧代靛玉红的制备和用途
CN113773243B (zh) * 2021-09-01 2023-01-06 大连理工大学 一种有机催化氧化吲哚自缩合制备异靛蓝类化合物的方法
WO2023060268A1 (en) 2021-10-08 2023-04-13 Azora Therapeutics, Inc. Derivatives of aryl hydrocarbon receptor agonists

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS617254A (ja) * 1984-06-20 1986-01-13 Isukura Sangyo Kk ビスインドリノンおよびそれを主成分とする制癌剤
AU4155697A (en) * 1996-08-23 1998-03-06 Sugen, Inc. Indolinone combinatorial libraries and related products and methods for the treatment of disease

Also Published As

Publication number Publication date
CA2333661A1 (en) 1999-12-09
DE69905712T2 (de) 2004-01-29
BR9910810A (pt) 2001-02-13
ES2194468T3 (es) 2003-11-16
IL139914A0 (en) 2002-02-10
JP2002516851A (ja) 2002-06-11
EP1079826A2 (en) 2001-03-07
AU762830B2 (en) 2003-07-03
DE69905712D1 (de) 2003-04-10
KR20010078722A (ko) 2001-08-21
ATE233560T1 (de) 2003-03-15
WO1999062503A3 (en) 2000-01-27
HUP0102240A2 (hu) 2001-11-28
WO1999062503A2 (en) 1999-12-09
AU4368799A (en) 1999-12-20
DK1079826T3 (da) 2003-06-23
NO20006027D0 (no) 2000-11-28
NO20006027L (no) 2001-01-22
EP1079826B1 (en) 2003-03-05

Similar Documents

Publication Publication Date Title
HUP0102240A3 (en) Use of indigoid bisindole derivatives for the manufacture of a medicament to inhibit cyclin dependent kinases
IL145743A0 (en) Indigoid bisindole derivatives
IL144668A (en) Use of a 4-h-1-benzopyran-4-one derivative for the preparation of a medicament for inhibiting smooth muscle cell proliferation
HUP0200310A3 (en) Use of tricyclic pyrazole derivatives for preparing pharmaceutical compositions and the new compounds
AU2001235691A1 (en) Use of paullone derivatives for making medicines
HUP0200819A2 (hu) Sejtméret által szabályozott humán h-sgk gátlóanyagait tartalmazó gyógyszer
HUP9903308A3 (en) Granuls for the preparation of fast-disintegrating and fast-dissolving compositions containing a high amount of drug
AUPP609198A0 (en) Use of non-peptidyl compounds for the treatment of insulin related ailments
HU9800535D0 (en) Use of pyrimidine derivatives for producing pharmaceutical compositions for preventing tumor
HU9800291D0 (en) Use of amido-pirimidine derivatives for producing pharmaceutical compositions for inhibiting decrease of glucose-metabolismus
IL138645A0 (en) Use of steroidal alkaloid derivatives as inhibitors of hedghog signalling pathways
HUP0200441A2 (hu) Tetrahidropiránszármazékok és terápiás szerként való alkalmazásuk és eljárás a vegyületek előállítására
HUP0002239A3 (en) The use of thienopyrimidine derivatives for combating fungi
AU2177001A (en) Use of indirubine derivatives for making medicines
ZA983602B (en) Use of tetrahydropyridine derivatives for the preparation of drugs for the treatment of diseases which cause demyelination
AU7622000A (en) Compounds for the treatment of viral-mediated diseases
AU2002231811A1 (en) Use of flumazenil to produce a medicament for the treatment of cocaine dependency
IL151765A0 (en) Hydroxyphenyl-piperazinyl-methyl-benzamide derivatives for the treatment of pain
HUP0102436A3 (en) Use of reboxetin for preparation of medicament for nervous disorders
HK1053424A1 (en) The use of exemestane for the preparation of a medicament for the first-line treatment of breast cancer
HUP0201667A2 (en) Oral form of administration
IL147496A0 (en) Preparation of a therapeutic composition
EP1003516A4 (en) METHOD FOR THE ADMINISTRATION OF CAMPTOTHECIN COMPOSITIONS FOR CANCER TREATMENT WITH REDUCED SIDE EFFECTS
IL149534A0 (en) Preparation of 3-substituted-4-arylquinolin-2-one derivatives
HUP0203900A3 (en) Use of substituted 4-amino-1-phenylbutan-2-ol compounds as medicaments

Legal Events

Date Code Title Description
FD9A Lapse of provisional protection due to non-payment of fees